Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track Designation for omaveloxolone for the treatment...
FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high r...
Novo Nordisk to buy RNAi therapy developer Dicerna for $3.3 billion
Novo Nordisk to buy RNAi therapy developer Dicerna for $3.3 billion
Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals for $38.25 per share in cash, or a total equity value of around $3.3 billion, the companies said Thursday.  ...
BridgeBio Pharma nabs $750M in non-dilutive debt financing
BridgeBio Pharma nabs $750M in non-dilutive debt financing
BridgeBio Pharma executed a definitive credit facility agreement with a syndicate of lenders for up to $750M in financing which replaces its $100M debt facility with Hercules.
Pfizer, US ink $5.29B deal for possible COVID-19 treatment
Pfizer, US ink $5.29B deal for possible COVID-19 treatment
The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it, the nation's largest purchase agreement yet...
Moderna seeks FDA approval to authorize booster shots for all adults
Moderna seeks FDA approval to authorize booster shots for all adults
Moderna filed an application Wednesday with the Food and Drug Administration seeking emergency use authorization of vaccine booster shots for all Americans ages 18 and up. ...
LOKELMA® granted Fast Track Designation in the US to reduce cardiovascular outcomes in patients on chronic hemodialysis with hyperkalemia
LOKELMA® granted Fast Track Designation in the US to reduce cardiovascular outcomes in patients on chronic hemodialysis with hyperkalemia
AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA® (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes ...
Blood biomarker identified that predicts type 2 diabetes many years before diagnosis
Blood biomarker identified that predicts type 2 diabetes many years before diagnosis

An AI-based diagnostic tool is being developed through a biotech startup.

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announc...
Pfizer Asks FDA to Clear Covid Pill for High-Risk Patients
Pfizer Asks FDA to Clear Covid Pill for High-Risk Patients
Pfizer Inc. asked U.S. regulators for emergency-use authorization of its Covid-19 pill that could play a critical role in further protecting high-risk patients from the disease’s worst effects. ...
Rice lab first to mimic molecule found in poppies. Undergraduate leads synthesis of scarce extract, possible drug precursor
Rice lab first to mimic molecule found in poppies. Undergraduate leads synthesis of scarce extract, possible drug precursor
A Rice University undergraduate student’s grit and talent paid off in a big way when she introduced the first synthesis of a rare and potentially potent molecule drawn from poppies.  ...
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
NICE has issued a positive recommendation for Arvelle Therapeutics’ cenobamate (Ontozry), for the treatment of focal-onset seizures in adults with uncontrolled epilepsy in England and Wales. ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand